New Milestone: The Bi-specific CD47XHER2 fusion protein, IMM2902 approved for clinical trial by National Medical Products Administration (NMPA)
June 30, 2021, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that the first-in-Class drug candidate, Bi-specific recombinant fusion protein targeting human CD47and HER2 named IMM2902 received clinical trial approval from the National Medical Products Administration (NMPA).This is the third new drug product based on CD47 of ImmuneOnco entered the clinical stage of development, and it is the cutting-edge product targeting CD47 and Her2 for immunotherapy of solid tumors, another major milestone for the company.
"We are pleased to learn that our clinical trial application for IMM2902 has been approved by the NMPA. IMM2902 is a bi-specific molecule for binding CD47 and HER2, developed based on our MAB-TRAP technology platform. The high affinity activity of HER2 enables the molecule to bind preferentially to tumor cells. at the same time, it retains the advantage feature of avoiding binding to human red blood cells, the "Antigenic sink", which greatly strengthens the tumor-specific synergistic effect of double targets. "We believe that IMM2902 has promising clinical value." Dr. Tian Wenzhi, founder of the company, is confident in IMM2902 clinical development..
The IMM2902 for injection is a new generation of bi-specific antibody with global intellectual property rights, which is developed based on the "MAB-TRAP" technic platform of ImmuneOnco. It targets CD47 and HER2
and inhibits the growth of tumor cells by accelerating the endocytosis and degradation of HER2. By blocking the "don't eat me" signal and activating the "eat me" signal on macrophages it can induce the phagocytosis of tumor cells. Macrophages then deliver the tumor antigen processed by phagocytosis to T cells, thus playing a powerful effect of tumor
immunotherapy. IMM2902 aims at indications of solid tumors such as breast, stomach and lung cancers that are HER2-positive.
Founded in June 2015 in the Zhangjiang Hi-Tech Park of the China (Shanghai) Pilot Free Trade Zone, ImmuneOnco focuses on development and research of anti-tumor immunotherapy products, including bispecific antibody-traps (mAb-Traps), novel recombinant proteins, and target-activated NK cell therapy. Our compounds aim to activate patients’own immune system to exert anti-tumor effects, and ultimately inhibit endless growth of tumor cells and reverse malignant symptoms, so that patients can gradually return to being healthy. Currently, several new anti-tumor products are in clinical development stage. ImmuneOnco is recognized by authorities as one of the ‘Top 50 Start-up Enterprises with the Most Investment Potential in Shanghai’ in 2016, the "Excellent Enterprise" in the 2017 China Innovation and Entrepreneurship Competition, and one of the winners of the "Enterprise Excellence Award" of Shanghai Science and Technology Entrepreneurship in 2017.
For further cooperation, please contact
Address: Room 502, 1043 HaLei Road, Pudong New Area, Shanghai, China
Building 7, Lane 908, Ziping Road, Pudong New Area, Shanghai, China
Tel. + 86 21 5835 6573